open access

Vol 74, No 1 (2024)
Research paper (original)
Published online: 2023-11-09
Get Citation

Increased prevalence of pancreatic neuroendocrine microadenomas in patients with intraductal papillary mucinous neoplasms – yet another example of exocrine-neuroendocrine interaction?

Łukasz Liszka1
·
Nowotwory. Journal of Oncology 2024;74(1):1-11.
Affiliations
  1. Department of Pathomorphology and Molecular Diagnostics, Medical University of Silesia, Katowice, Poland

open access

Vol 74, No 1 (2024)
Original articles – Pancreatic tumors
Published online: 2023-11-09

Abstract

Introduction.  Intraductal papillary mucinous neoplasms (IPMN) and neuroendocrine tumours (NET) may develop simultaneously in the pancreas. Neuroendocrine microadenomas (NMA) are precursor lesions for NET. The study aimed to determine the prevalence of NMA/NET in patients with IPMN in a series of resection specimens.

Material and methods.Some 232 prospectively gathered specimens were included and examined histopathologically: 51 IPMN, 114 conventional pancreatic ductal carcinomas (PDAC) and 67 ampullary carcinomas (AMPCA).

Results.NET were rare in the study samples (single cases among IPMN and AMPCA, and two cases among PDAC). In contrast, NMA were frequently found in IPMN specimens when compared to samples of PDAC and AMPCA (27.45%; 7.89%, and 7.46%, respectively, p < 0.001). Two NMA in IPMN group were related to ducts, but no case of composite (clonal) IPMN/NMA was found.

Conclusions.IPMN specimens were enriched in NMA but not in NET. IPMN/NMA association may serve as a model of exocrine-neuroendocrine interaction.   

Abstract

Introduction.  Intraductal papillary mucinous neoplasms (IPMN) and neuroendocrine tumours (NET) may develop simultaneously in the pancreas. Neuroendocrine microadenomas (NMA) are precursor lesions for NET. The study aimed to determine the prevalence of NMA/NET in patients with IPMN in a series of resection specimens.

Material and methods.Some 232 prospectively gathered specimens were included and examined histopathologically: 51 IPMN, 114 conventional pancreatic ductal carcinomas (PDAC) and 67 ampullary carcinomas (AMPCA).

Results.NET were rare in the study samples (single cases among IPMN and AMPCA, and two cases among PDAC). In contrast, NMA were frequently found in IPMN specimens when compared to samples of PDAC and AMPCA (27.45%; 7.89%, and 7.46%, respectively, p < 0.001). Two NMA in IPMN group were related to ducts, but no case of composite (clonal) IPMN/NMA was found.

Conclusions.IPMN specimens were enriched in NMA but not in NET. IPMN/NMA association may serve as a model of exocrine-neuroendocrine interaction.   

Get Citation

Keywords

pathology; pancreas; pancreatic neoplasms; pancreatic intraductal neoplasms; islet-cell adenoma

About this article
Title

Increased prevalence of pancreatic neuroendocrine microadenomas in patients with intraductal papillary mucinous neoplasms – yet another example of exocrine-neuroendocrine interaction?

Journal

Nowotwory. Journal of Oncology

Issue

Vol 74, No 1 (2024)

Article type

Research paper (original)

Pages

1-11

Published online

2023-11-09

Page views

182

Article views/downloads

204

DOI

10.5603/njo.97450

Bibliographic record

Nowotwory. Journal of Oncology 2024;74(1):1-11.

Keywords

pathology
pancreas
pancreatic neoplasms
pancreatic intraductal neoplasms
islet-cell adenoma

Authors

Łukasz Liszka

References (26)
  1. WHO classification of tumors. Digestive system tumors. WHO, IARC, Lyon 2019.
  2. Marrache F, Cazals-Hatem D, Kianmanesh R, et al. Endocrine tumor and intraductal papillary mucinous neoplasm of the pancreas: a fortuitous association? Pancreas. 2005; 31(1): 79–83.
  3. Partelli S, Giannone F, Schiavo Lena M, et al. Is the Real Prevalence of Pancreatic Neuroendocrine Tumors Underestimated? A Retrospective Study on a Large Series of Pancreatic Specimens. Neuroendocrinology. 2019; 109(2): 165–170.
  4. Manuel-Vazquez A, Ramia JM, Latorre-Fragua R, et al. Pancreatic Neuroendocrine Tumors and Intraductal Papillary Mucinous Neoplasm of the Pancreas: A Systematic Review. Pancreas. 2018; 47(5): 551–555.
  5. Moriyoshi K, Minamiguchi S, Miyagawa-Hayashino A, et al. Collision of extensive exocrine and neuroendocrine neoplasms in multiple endocrine neoplasia type 1 revealed by cytogenetic analysis of loss of heterozygosity: a case report. Pathol Int. 2013; 63(9): 469–475.
  6. Stukavec J, Jirasek T, Mandys V, et al. Poorly differentiated endocrine carcinoma and intraductal papillary-mucinous neoplasm of the pancreas: Description of an unusual case. Pathol Res Pract. 2007; 203(12): 879–884.
  7. Kadota Y, Shinoda M, Tanabe M, et al. Concomitant pancreatic endocrine neoplasm and intraductal papillary mucinous neoplasm: a case report and literature review. World J Surg Oncol. 2013; 11: 75.
  8. Sahora K, Crippa S, Zamboni G, et al. Intraductal papillary mucinous neoplasms of the pancreas with concurrent pancreatic and periampullary neoplasms. Eur J Surg Oncol. 2016; 42(2): 197–204.
  9. Larghi A, Stobinski M, Galasso D, et al. Concomitant intraductal papillary mucinous neoplasm and pancreatic endocrine tumour: Report of two cases and review of the literature. Dig Liver Dis. 2009; 41(10): 759–761.
  10. Goh BKP, Ooi LL, Kumarasinghe MP, et al. Clinicopathological features of patients with concomitant intraductal papillary mucinous neoplasm of the pancreas and pancreatic endocrine neoplasm. Pancreatology. 2006; 6(6): 520–526.
  11. Hashimoto Y, Murakami Y, Uemura K, et al. Mixed ductal-endocrine carcinoma derived from intraductal papillary mucinous neoplasm (IPMN) of the pancreas identified by human telomerase reverse transcriptase (hTERT) expression. J Surg Oncol. 2008; 97(5): 469–475.
  12. Gill KR, Scimeca D, Stauffer J, et al. Pancreatic neuroendocrine tumors among patients with intraductal papillary mucinous neoplasms: real association or just a coincidence? JOP. 2009; 10(5): 515–517.
  13. Schiavo Lena M, Cangi MG, Pecciarini L, et al. Evidence of a common cell origin in a case of pancreatic mixed intraductal papillary mucinous neoplasm-neuroendocrine tumor. Virchows Arch. 2021; 478(6): 1215–1219.
  14. Chen J, Wang P, Lv Ke, et al. Case report: composite pancreatic intraductal papillary mucinous neoplasm and neuroendocrine tumor: a new mixed neuroendocrine-non-neuroendocrine neoplasm? Diagn Pathol. 2021; 16(1): 108.
  15. Okawa Y, Tsuchikawa T, Hatanaka KC, et al. Clinical Features of Pancreatic Neuroendocrine Microadenoma: A Single-Center Experience and Literature Review. Pancreas. 2022; 51(4): 338–344.
  16. Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci. 1991; 36(7): 933–942.
  17. Bartow SA, Mukai K, Rosai J. Pseudoneoplastic proliferation of endocrine cells in pancreatic fibrosis. Cancer. 1981; 47(11): 2627–2633, doi: 10.1002/1097-0142(19810601)47:11<2627::aid-cncr2820471118>3.0.co;2-c.
  18. Lee MiRi, Harris C, Baeg KJ, et al. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States. Clin Gastroenterol Hepatol. 2019; 17(11): 2212–2217.e1.
  19. Grimelius L, Hultquist GT, Stenkvist B. Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material. Virchows Arch A Pathol Anat Histol. 1975; 365(4): 275–288.
  20. Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022; 33(1): 115–154.
  21. Leoncini E, Carioli G, La Vecchia C, et al. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol. 2016; 27(1): 68–81.
  22. Capurso G, Falconi M, Panzuto F, et al. Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients. Am J Gastroenterol. 2009; 104(12): 3034–3041.
  23. Feola T, Puliani G, Sesti F, et al. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study. J Endocrinol Invest. 2022; 45(4): 849–857.
  24. Capurso G, Boccia S, Salvia R, et al. Italian Association for Study of Pancreas (AISP), Intraductal Papillary Mucinous Neoplasm (IPMN) Study Group. Risk factors for intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a multicentre case-control study. Am J Gastroenterol. 2013; 108(6): 1003–1009.
  25. Overton DL, Mastracci TL. Exocrine-Endocrine Crosstalk: The Influence of Pancreatic Cellular Communications on Organ Growth, Function and Disease. Front Endocrinol (Lausanne). 2022; 13: 904004.
  26. Kenig J, Richter P. Pancreatoduodenectomy due to cancer in the older population. Nowotwory. Journal of Oncology. 2021; 71(5): 321–327.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl